

REMARKS

Reconsideration of the present application in view of the above amendments in the following remarks respectively requested.

I. STATUS OF THE CLAIMS

Claims 54, 55 – 66, 68 - 89 and 91 – 99 are now pending in the present application. Claims 53, 67 and 90 have been canceled and new claims 91 - 99 have been added. Claims 54, 57 -59, 62, 64, 68 – 89 have been amended.

Support for the amendments and for the new claims can be found throughout the present specification and more specifically as follows.

SUPPORT FOR CLAIM 1 AMENDMENTS

Support for the amendments to claim 54 is throughout the present specification, including particularly original claim 56. The following table provides a non-comprehensive identification of the location(s) in the specification which support the limitations, other than the limitations derived from original claim 3, which have been added by the present or prior amendments:

CLAIM REQUIREMENT	SPECIFICATION SUPPORT	RELEVANCE OF THE PASSAGE
“fluoroalkene having a total of at least four halogen substituents”	Page 6, lines 21 – 30	Tetrafluoropropenes contain four (4) halogens
	Page 22, Table I (first row)	Pentafluoropropenes containd five (5) halogens HFO-1225ye (CF ₃ CF=CFH) contains five halogens
“at least three of said halogen substituents being F”	Page 6, lines 4 – 5	“Y is CF ₃ ” in Formula II

CLAIM REQUIREMENT	SPECIFICATION SUPPORT	RELEVANCE OF THE PASSAGE
“at least one of said halogen substituents being located on an unsaturated, non-terminal carbon atom”	Page 22, Table I	<p>HFO-1225ye (CF₃CF=CFH) (a halogen, F, is on the unsaturated non-terminal carbon)</p> <p>HFO-1234yf (CF₃CF=CH₂) (a halogen, F, is on the unsaturated non-terminal carbon)</p>
“[the Formula II compound has] not more than one F on the terminal unsaturated carbon”	<p>Page, 7, lines 1 - 7</p> <p>Page 22, Table I</p>	<p>High toxicity is associated with compounds having more than one F on the terminal unsaturated carbon</p> <p>HFO-1225ye (CF₃CF=CFH) (only one F is on the unsaturated non-terminal carbon)</p> <p>HFO-1234yf (CF₃CF=CH₂) (no Fs are on the unsaturated non-terminal carbon)</p>

SUPPORT FOR DEPENDENT CLAIM AMENDMENTS

Many of the claim amendments are made to correct obvious clarifications and modifications to correct dependency references, and no citation of support is required for such amendments.

The amendment to claims 72 and 87, which clarify that HFO-1234ze is included in the composition but is not a Formula II compound, are found throughout the specification but particularly at page 8, lines 19 – 22 (HFO-1234ze is a Formula I compound).

SUPPORT FOR NEW CLAIMS

Support for new claims 91 - 93 is found at page 8, lines 19 – 30.

Support for new claim 94 is found at page 9, lines 3 – 5.

Support for new claims 95 – 97 is found at page 9, lines 5 – 9.

Support for new claim 98 is found at page 19, lines 1 – 18.

Support for new claim 99 is found at page 20, lines 5 - 9.

II. THE CLAIMED SUBJECT MATTER

The present application contains only one independent claim, namely claim 54. This claim and all claims in the application, as now presented, relate to compositions comprising a compound of Formula II, with certain specific requirements, and at least one adjuvant.

III. CONCLUSION

Applicants believe that the claims as now pending patently distinguished over the prior art, and an early notice thereof is hereby earnestly solicited.

Applicants are considering, and hereby reserve the right, to also file supplemental remarks later today to further aid the Examiner in understanding the patentable differences between the claimed subject matter and the prior art. Should the Examiner have any questions regarding this paper, she is invited to contact the undersigned at the telephone number indicated below.

Respectfully submitted,

Date:

Joseph F. Posillico
Registration No. 32,290
Synnestvedt & Lechner
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Telephone: (215) 923-4466
Facsimile: (215) 923-2189